The FDA has granted accelerated approval of Wegovy® (semaglutide) for adults with moderate to advanced metabolic ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...